Cancer Immunotherapy and Biomarkers

The paper investigates immune cell senescence in melanoma patients and finds that non-responders to immunotherapy have higher senescence in immune cells compared to responders.

This study shows that isoflavones in the diet impair anti-PD1 therapy response in breast cancer models, regardless of dietary fiber or SCFA levels, and that ER blockade can restore responsiveness.

This study shows dietary restriction enhances CD8+ T cell ketolysis, improving mitochondrial function and anti-tumor immunity by reducing exhaustion.

This study shows that inhibiting nonsense-mediated mRNA decay enhances tumour immunogenicity, drives immunoediting, and improves checkpoint blockade efficacy in preclinical models.

This study shows that B-cell depletion or TIM-1 targeting enhances immunotherapy efficacy in HCC by reducing B-cell-mediated immunosuppression and improving antigen presentation.

This study identifies metabolic biomarkers predictive of immune checkpoint inhibitor response in gynecologic cancers using flux balance analysis and machine learning.

This study shows that combining SUMO E1 inhibition with TIGIT blockade enhances anti-tumor immunity in pancreatic cancer by reducing regulatory T cells and improving T cell reactivity.

This study develops antibody-peptide epitope conjugates (APECs) to enhance anti-tumor activity in ICB-resistant HNSCC by leveraging viral peptide-loaded MHC I proteins and protease activity.

This study uses single-cell RNA sequencing to analyze immune and stromal differences between primary tumors and metastatic lymph nodes in ESCC, revealing distinct exhaustion trajectories and suppressive circuits.

This study shows that inhibiting Neuropilin-1 slows B16-F10 melanoma progression and reduces Treg-mediated immunosuppression.

This study examines how checkpoint receptors in circulating γδ T cells correlate with cancer immunotherapy outcomes, identifying potential prognostic markers and therapeutic targets.

The paper models PD-L1 dynamics in response to immunotherapy, showing that PD-L1 upregulation leads to treatment failure, while PD-1/PD-L1 blockade improves anti-tumor responses.

This study identifies PD-1's role in maintaining stem-like CD8+ T cells through TCR affinity regulation and signaling fine-tuning, showing its impact on immunotherapy efficacy.

This study shows PD-1 blockade during T cell priming promotes an intermediate-exhausted CD8 T cell state that supports durable anti-tumor immunity after surgery and metastatic challenge, better than effector or memory-like T cells.

This study links oncogenic RAS activity to immune priming and adenosine-driven immune evasion in lung adenocarcinoma, showing both pro-immunogenic and immunosuppressive effects.

The paper identifies riboflavin-auxotrophic Enterococcus spp. that synergize with metabolites to boost MR1 expression and activate MAIT cells in the tumor microenvironment.

This study identifies pre-treatment naive CD4+ T cell abundance as a predictor of severe irAEs in patients receiving anti-PD-1/CTLA4 checkpoint inhibitor therapy for melanoma.

This study shows TAp73 regulates lipid metabolism in lung tumor microenvironment to enhance anti-tumor immunity through T-cell activation.

The paper introduces TCPGdb, a database integrating T cell perturbation screens to identify critical regulators of T cell function and anti-tumor persistence.

This paper identifies NOTCH1 and MYB as dual transcriptional drivers of immune suppression in salivary adenoid cystic carcinoma, revealing their roles in suppressing T-cell and B-cell immunity through distinct signaling pathways.

This study shows that aging reduces T cell recruitment in breast cancer by decreasing Cxcl9/Cxcl10 expression in tumor cells, leading to weakened anti-tumor immunity.

This study shows that targeting the STING-ATM axis with a STING agonist overcomes radiotherapy-induced immune suppression in nasopharyngeal carcinoma, enhancing anti-tumor immunity and tumor control.

This study shows that hematopoietic Tet2 inactivation improves immune checkpoint blockade response in mice and is associated with better clinical outcomes in melanoma patients with TET2-driven clonal hematopoiesis.

This study identifies risk factors and patterns of immune-related adverse events (irAEs) in patients receiving immune checkpoint inhibitors using real-world data.

This study identifies microbiome-derived protein biomarkers for predicting immunotherapy response and toxicity in melanoma without relying on taxonomic classification.

This study shows IGF-1 suppresses immune-related pathways in prostate cancer cells, reducing antigen presentation and increasing PD-L1, which may explain poor immunotherapy response.

IMMUNIA identifies immunoregulatory surfaceome genes using multi-LLM reasoning, highlighting novel stromal immune checkpoint regulators.

This study shows that HuR promotes immune evasion in PDAC by inhibiting T cell infiltration and function, suggesting HuR as a therapeutic target with immunotherapy.